Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone 2016-2017 Formulations
NCT02908269Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) and trivalent inactivated influenza vaccine high-dose in influenza (3 arms), sponsored by Sanofi. Primary endpoint: Number of Participants Reporting Solicited Injection Site Reactions and Systemic Reactions at 7 days. Started Sep 2016; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)trivalent inactivated influenza vaccine high-dose
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02908269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908269.